Stockscreener 앱 받기
4.15
3.49%
0.14
시간 외 거래:
4.15
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path - MyChesCo
MSN Money - MSN
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR) - The Globe and Mail
Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC - MarketBeat
LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Millennium Management (LRMR) reports 3.5% ownership; 3,625,278 shares - Stock Titan
Larimar Therapeutics Publishes Cross-Species Findings - GlobeNewswire
Larimar Therapeutics stock dips after pricing $100M share offering - MSN
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics launches proposed $75 million public offering - MSN
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Larimar Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Friedreich's Ataxia Pipeline Enters a Transformative Era with - openPR.com
Friedreich’s Ataxia Pipeline Enters a Transformative Era with 20+ Therapies and Strong Clinical Momentum from Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics | DelveInsight - Barchart
Larimar Therapeutics (LRMR) Stock: Pricing Evaluation | Q4 2025: Profit DisappointsNet Margin - Cổng thông tin điện tử tỉnh Tây Ninh
Larimar Therapeutics (LRMR) to Release Earnings on Wednesday - MarketBeat
Larimar Therapeutics (NASDAQ: LRMR) targets director votes and higher authorized share count - Stock Titan
[ARS] Larimar Therapeutics, Inc. SEC Filing - Stock Titan
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics (NASDAQ: LRMR) asks shareholders to double authorized shares to 215M - Stock Titan
Analysts Set Larimar Therapeutics Price Target at $16.50 - National Today
Investment Review: Is Larimar Therapeutics Inc currently under institutional pressure2026 Breakouts & Breakdowns & Stepwise Swing Trade Plans - baoquankhu1.vn
Can Larimar Therapeutics (LRMR) Stock Maintain Growth | Price at $5.14, Up 0.98%Social Buzz - Cổng thông tin điện tử tỉnh Tây Ninh
Pullback Watch: Is Larimar Therapeutics Inc forming a double bottom2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Pharma News: Is Larimar Therapeutics Inc impacted by rising ratesWeekly Stock Summary & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Will Larimar Therapeutics (LRMR) Stock Rise in 2026 | Price at $4.79, Down 0.10%Hot Community Stocks - Xã Thanh Hà
Larimar surges on FDA breakthrough status for lead asset - MSN
LRMR Technical Analysis & Stock Price Forecast - Intellectia AI
LRMR PE Ratio & Valuation, Is LRMR Overvalued - Intellectia AI
Biotech Larimar heads to Miami for back-to-back investor meetings in March - Stock Titan
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital - MarketBeat
LRMR SEC FilingsLarimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Larimar reports results, advances Nomlabofusp toward FDA filing - MSN
Earnings Recap: Does Larimar Therapeutics Inc have consistent dividend growthMarket Growth Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Buyback Watch: Is Larimar Therapeutics Incs growth already priced in2026 Weekly Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Larimar Therapeutics Inc impacted by rising ratesProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13 - MSN
Profit Recap: Will Larimar Therapeutics Inc stock hit new highs in YEAR2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Insider Monkey
1.77%
0.25%
자본화:
|
볼륨(24시간):